Targets › NKG2DL
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2027.
Open in Phaseline: the race on NKG2DL, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Peking University People's Hospital | CT0890B NKG2DL-targeted CAR-T cell therapy | NKG2DL | Phase 1 | AML | Dec 2027 |
AML (1)
other (1)
Peking University People's Hospital (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.